PIRAMAL CRITICAL is a generic drug manufacturer focused on Oncology, Metabolic.
PIRAMAL CRITICAL's Key Drugs
PIRAMAL CRITICAL's core commercial portfolio centers on MITIGO, spanning Oncology and Metabolic — its most strategically important drugs approved in the last 15 years.
PIRAMAL CRITICAL's Recent FDA Approvals
PIRAMAL CRITICAL secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
PIRAMAL CRITICAL's Therapeutic Areas
PIRAMAL CRITICAL's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Metabolic, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PIRAMAL CRITICAL's Top Competitors
PIRAMAL CRITICAL's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PIRAMAL CRITICAL Pipeline Snapshot
Active clinical trials for PIRAMAL CRITICAL across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • MITIGO leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 1994-07-29
- Latest
- 2025-10-16
- Applications
- 12